July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
In vitro analysis of RUNX1 and VEGF pathway interactions
Author Affiliations & Notes
  • Hannah Whitmore
    Schepens Eye Research Institute - MEEI, Massachusetts, United States
  • Dhanesh Amarnani
    Schepens Eye Research Institute - MEEI, Massachusetts, United States
  • Santiago Delgado-Tirado
    Schepens Eye Research Institute - MEEI, Massachusetts, United States
  • Joseph Arboleda-Velasquez
    Schepens Eye Research Institute - MEEI, Massachusetts, United States
  • Leo A. Kim
    Schepens Eye Research Institute - MEEI, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Hannah Whitmore, None; Dhanesh Amarnani, None; Santiago Delgado-Tirado, None; Joseph Arboleda-Velasquez, None; Leo Kim, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 2687. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hannah Whitmore, Dhanesh Amarnani, Santiago Delgado-Tirado, Joseph Arboleda-Velasquez, Leo A. Kim; In vitro analysis of RUNX1 and VEGF pathway interactions. Invest. Ophthalmol. Vis. Sci. 2019;60(9):2687. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Neovascularization is a pathological feature of proliferative diabetic retinopathy (PDR). Current anti-angiogenic therapies typically target vascular endothelial growth factor (VEGF) and are effective treatments for a number of angiogenic diseases of the eye. We have recently identified glucose-dependent up-regulation of Runt-related transcription factor 1 (RUNX1) in vascular endothelial cells and its role in PDR. We have identified RUNX1 as a novel pathway of potential therapeutic interest and implicate RUNX1 as a mediator of aberrant retinal angiogenesis. The aim of this study is to investigate the role of VEGF in regulating RUNX1 expression.

Methods : Human Microvascular Endothelial cells (HMRECs) were cultured in endothelial growth media, supplemented with high concentrations of D-glucose (30 mM), h-VEGF (5 or 10 ng/ml) or aflibercept (40 mg/ml) for 12 to 48 hours. The effect of glucose and VEGF on RUNX1 mRNA levels was evaluated by Quantitative RT-PCR (qRT-PCR). Western blot analyses with antibodies against RUNX1 and β-actin were performed to confirm protein expression of RUNX1.

Results : 30 mM D-glucose increased RUNX1 RNA (1.22 ± 0.03 fold, p < 0.05) and protein expression (1.28 ± 0.03 fold, p < 0.05) in HMRECs after 48 hours of treatment. Treatment of HMRECs with 5 or 10 ng/ml of VEGF had no effect on RUNX1 RNA levels at 12 hours but caused a decrease in RUNX1 after 48 hours (0.72 ± 0.06, p < 0.05). Treatment with aflibercept caused a non-significant increase in RUNX1 RNA and protein expression.

Conclusions : These findings are consistent with previous findings that RUNX1 is involved in the endothelial cell response to glucose and mediate the behavior of HMRECs in angiogenesis. The results also indicate that increased expression of RUNX1 as found in pathologic ocular angiogenesis is VEGF-independent and thus suggests an alternative VEGF-independent mechanism of endothelial cell behavior in ocular pathology.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×